Serum trough SB5 levels: A comparison of two different immunoassays for the monitoring of biosimilar adalimumab treatment in patients with inflammatory bowel disease

(1) ISCARE IVF & Charles University,Prague,Czech Republic



This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019